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Abstract
The objective of the present study was to determine if there is a relationship between serum levels of brain-derived neurotrophic factor 
(BDNF) and the number of T2/fluid-attenuated inversion recovery (T2/FLAIR) lesions in multiple sclerosis (MS). The use of magnetic 
resonance imaging (MRI) has revolutionized the study of MS. However, MRI has limitations and the use of other biomarkers such 
as BDNF may be useful for the clinical assessment and the study of the disease. Serum was obtained from 28 MS patients, 18-50 
years old (median 38), 21 women, 0.5-10 years (median 5) of disease duration, EDSS 1-4 (median 1.5) and 28 healthy controls, 
19-49 years old (median 33), 19 women. BDNF levels were measured by ELISA. T1, T2/FLAIR and gadolinium-enhanced lesions 
were measured by a trained radiologist. BDNF was reduced in MS patients (median [range] pg/mL; 1160 [352.6-2640]) compared 
to healthy controls (1640 [632.4-4268]; P = 0.03, Mann-Whitney test) and was negatively correlated (Spearman correlation test, 
r = -0.41; P = 0.02) with T2/FLAIR (11-81 lesions, median 42). We found that serum BDNF levels were inversely correlated with 
the number of T2/FLAIR lesions in patients with MS. BDNF may be a promising biomarker of MS.
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Multiple sclerosis (MS) is the most prevalent demyeli-
nating disease affecting young people around the world. 
The use of magnetic resonance imaging (MRI) in clinical 
practice revolutionized the process of MS diagnosis. MRI 
is also important for the clinical follow-up of MS patients, 
contributing to the process of definition of MS relapses 
and disease progression. Indeed, the burden of T1 and T2 
lesions has been reported to correlate with MS progres-
sion (1,2). As a result, MRI is being increasingly used as a 
marker for the diagnosis and follow-up of disease activity 
and progression in MS patients (3,4).
Besides imaging parameters, treatment decisions may 
benefit from other accessible clinical biomarkers. Some pu-
tative biomarkers have been proposed for MS (5). However, 
at present, no validated biomarkers are available to diagnose 
the disease, to monitor or predict its progression, or to aid 
in the assessment of the effects of early treatment (6).
Brain-derived neurotrophic factor (BDNF) belongs to a 
class of proteins expressed in the nervous system of mam-
mals called neurotrophins, which have been related to neu-
ronal development and survival (7). BDNF levels are altered 
in a variety of neurological diseases. For instance, serum 
BDNF from Alzheimer’s disease patients is decreased when 
compared to healthy controls (8). BDNF is also diminished 
in patients with Parkinson’s disease and correlates with the 
severity of motor symptoms and the span of this disease 
(9). Increased expression of a high-affinity BDNF receptor 
was found in T-cell lines from MS patients (10), whereas 
low BDNF synthesis by peripheral blood mononuclear cells 
(PBMC) was related to reduced neuroprotection (11,12). 
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Therefore, BDNF may be a potential clinical 
marker of disease progression.
In the present study, we determined if there 
was a correlation between the number of MRI 
T1, T2, and gadolinium-enhanced (Gad+) le-
sions in patients with relapsing remittent MS 
(RRMS) and BDNF serum levels.
Patients and Methods
Patients with a definite diagnosis of RRMS 
according to the McDonald criteria (13) were 
selected for this study if they met the follow-
ing inclusion criteria: less than 10 years of 
disease, clinical and/or radiological evidence 
of at least one relapse in the last 12 months, 
and Expanded Disability Status Scale (EDSS) 
score below 5 (14). Relapses were defined as 
an acute new symptom or worsening of old 
symptoms topographically related to a white matter lesion in 
the central nervous system (CNS) that lasted over 24 h (14). 
Blood was collected at least 3 months after the last relapse. 
For comparison, healthy subjects were invited to participate. 
Patients and controls were submitted to one MRI scan.
MRI was performed within 1 week after collecting the 
blood sample using a 1.5 Tesla apparatus (GE Xcite II, 
2004, USA). T2-weighted images, conventional spin-echo 
T1-weighted images, and fluid-attenuated inversion recov-
ery (FLAIR) images were obtained in sagittal, coronal and 
axial sequences (15). A radiologist blind to the medical 
status of the patients analyzed all exams and performed 
manual counting of the number of T1 hypointense, T2/
FLAIR hyperintense and Gad+ lesions in axial images with 
3-mm long slices.
These data were correlated with the serum levels of 
BDNF assessed by ELISA. All blood samples were collected 
in the morning, and the serum was separated and frozen 
at -70°C until the time for BDNF measurement. BDNF was 
measured by sandwich ELISA according to the protocol 
provided by the manufacturer (R&D Systems, USA). Assays 
were made in duplicate on the same day and intra-assay 
variability was less than 5%. 
Nonparametric analysis was performed using Mann-
Whitney and Kruskal-Wallis tests for two or more unpaired 
data, Wilcoxon and Friedman tests for two or more paired 
data, and the Spearman test for correlation. The P value 
was set at 0.05.
Results
The demographic and clinical features of MS patients 
and controls are summarized in Table 1.
BDNF was reduced in MS patients (median [range] pg/
mL; 1160 [352.6-2640]) compared to healthy controls (1640 
[632.4-4268]; P = 0.03, Mann-Whitney test). No correlation 
was found between BDNF levels and age (P = 0.1) or gender 
(P = 0.1) of patients and controls, or between BDNF levels 
and time of disease onset (P = 0.2) or EDSS (P = 0.2).
BDNF levels in serum from patients correlated negatively 
with the number of T2/FLAIR lesions (r = -0.41; P = 0.02; 
Figure 1). No correlation was found between BDNF levels 
and T1 (P = 0.46) or Gad+ lesions (P = 0.85).
Discussion
We report here that serum levels of BDNF are inversely 
correlated with the number of T2/FLAIR hyperintense le-
sions in MS patients. 
Previous reports have established a correlation between 
Figure 1. BDNF levels are inversely correlated with the number 
of T2/FLAIR lesions determined by MRI. Serum from MS pa-
tients (N = 28) was collected and BDNF levels were measured by 
ELISA. There was a significant negative correlation (P = 0.0292) 
between BDNF levels and T2/FLAIR lesions. BDNF = brain-de-
rived neurotrophic factor; T2/FLAIR = T2/fluid-attenuated inver-
sion recovery.
Table 1. Clinical and demographic details of multiple sclerosis (MS) patients 
and controls.
Healthy controls 
(N = 28)
MS patients 
(N = 28)
Females 19 21
Age, years (mean ± SD) 33.6 ± 9.5 33.9 ± 10.2
Disease duration, years (mean ± SD) - 5.2 ± 3.2
EDSS (mean ± SD) - 1.8 ± 0.8
Number of relapses in the first 2 years, 
 median (range)
- 2 (1-5)
Immunomodulatory therapy, N (%) -
IFN-β 17 (58.6%)
GA 1 (3.4%)
EDSS = Expanded Disability Status Scale; IFN-β = interferon beta; GA = glati-
ramer acetate. 
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the burden of T2 lesions and clinical outcome during short-
term follow-up (16,17). Furthermore, the load of T2 lesions 
above all other MRI findings was the best marker of MS activ-
ity in the early years of the disease and the best parameter 
correlated with disability in long-term follow-up (4). Therefore, 
BDNF may be seen as a promising biomarker of MS.
Since circulating levels of BDNF are correlated with its 
CNS concentration (18) and that load of T2/FLAIR lesions 
indicates demyelination of various degrees and neuronal 
damage (19,20), decreased circulating levels of BDNF may 
be associated with reduced synthesis of the molecule in the 
CNS and, hence, loss of neuroprotective support. Indeed, 
the present result agrees with the putative protective role 
of BDNF in neurodegenerative diseases (21,22). MS pa-
tients present lower levels of circulating BDNF compared 
to healthy controls, but these levels tend to increase after a 
relapse (23,24). An inverse correlation between BDNF syn-
thesis by PBMC and cognitive performance of MS patients 
has also been reported, reinforcing the view of BDNF as 
a neuroprotective molecule (25). Moreover, immune cells 
can secrete BDNF, and a positive association between 
synthesis of BDNF by PBMC and white matter volume 
has been reported to occur in MS (26). Some investigators 
even hypothesized that neuronal repair mechanisms act 
up to a threshold above which the repair cannot continue, 
and this threshold is correlated with the accumulation of 
lesions on T2 (4,17). 
The absence of correlation between T1 lesions and BDNF 
levels may be due to the T1 lesions themselves indicating 
chronic lesions (19). If BDNF is considered to be part of a 
repair mechanism, it cannot be correlated with lesions that 
express a chronic neuronal loss. Moreover, T1 and Gad+ le-
sions may disappear after some time, but every lesion, new 
or old, leaves a footprint in T2/FLAIR imaging (20).
Our study has some drawbacks such as the small 
number of MS patients enrolled and the fact that it was 
not possible to stratify the sample and to control the effect 
of immunomodulatory treatment on BDNF levels. Manual 
counting of MRI lesions is not the most accurate form to 
measure the burden of demyelinating lesions, but is the 
most feasible one in clinical practice. 
In conclusion, BDNF may be used as a biomarker of 
MS, although further studies are needed to confirm this 
preliminary finding.
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